Stockreport

Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of Up to $35 Million

Elutia, Inc. - Class A  (ELUT) 
PDF – Transaction Reflects Increasing Strategic Focus on Proprietary Drug-Eluting Biomatrix Platform – SILVER SPRING, Md., Sept. 18, 2023 (GLOBE NEWSWIRE) -- Elutia Inc [Read more]